Skip to main content


Investigational New Drugs

Investigational New Drugs 4/2015

Ausgabe 4/2015

Inhaltsverzeichnis ( 23 Artikel )

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids

Emil Bujak, Francesca Pretto, Dario Neri

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines

Federica Tonissi, Laura Lattanzio, Marco C. Merlano, Lucia Infante, Cristiana Lo Nigro, Ornella Garrone

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

Xinmei Xie, Lin Wang, Wenliang Yang, Ruishuang Yu, Qingli Li, Xiaobin Pang

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis

Sarah Schott, Sonia Vallet, Robert J. Tower, Seema Noor, Sanjay Tiwari, Christian Schem, Christian Busch

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties

Amna Ali, Timothy J. Burns, Jacob D. Lucrezi, Sheldon W. May, George R. Green, Diane F. Matesic

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs

Ekaterina Schreiber-Brynzak, Erik Klapproth, Christine Unger, Irene Lichtscheidl-Schultz, Simone Göschl, Sarah Schweighofer, Robert Trondl, Helmut Dolznig, Michael A. Jakupec, Bernhard K. Keppler

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015 Open Access

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer

Philippe Collery, Ahmed Mohsen, Anthony Kermagoret, Samantha Corre, Gérard Bastian, Alain Tomas, Ming Wei, François Santoni, Nadia Guerra, Didier Desmaële, Jean d’Angelo

01.08.2015 | PRECLINICAL STUDIES | Ausgabe 4/2015

Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cells

Victor Kuete, Arno R. Nanfack Donfack, Armelle T. Mbaveng, Maen Zeino, Pierre Tane, Thomas Efferth

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, Hagop Kantarjian, Martha Arellano, Emily A. Knight, Hao Xiong, Qin Qin, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Daniel H. Albert, Brian Oliver, Mark D. McKee, Justin L. Ricker, Hanna Jean Khoury

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015 Open Access

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Hidehito Horinouchi, Noboru Yamamoto, Yutaka Fujiwara, Ikuo Sekine, Hiroshi Nokihara, Kaoru Kubota, Shintaro Kanda, Shigehiro Yagishita, Hiroshi Wakui, Satoru Kitazono, Hidenori Mizugaki, Takuto Tokudome, Tomohide Tamura

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Zahi Mitri, Cansu Karakas, Caimiao Wei, Brian Briones, Holly Simmons, Nuhad Ibrahim, Ricardo Alvarez, James L. Murray, Khandan Keyomarsi, Stacy Moulder

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)

Joanne W. Chiu, Kelvin Chan, Eric X. Chen, Lillian L. Siu, Albiruni R. Abdul Razak

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors

Mark J. Ratain, David Geary, Samir D. Undevia, Cinthya Coronado, Vicente Alfaro, Jorge L. Iglesias, Richard L. Schilsky, Bernardo Miguel-Lillo

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

Rabih Said, Razelle Kurzrock, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Jennifer J. Wheler, Filip Janku, Bryan K. Kee, Savita Bidyasar, Joann Lim, Michael Wallace, Apostolia M. Tsimberidou

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

Khanh Do, Giovanna Speranza, Lun-Ching Chang, Eric C. Polley, Rachel Bishop, Weimin Zhu, Jane B. Trepel, Sunmin Lee, Min-Jung Lee, Robert J. Kinders, Larry Phillips, Jerry Collins, John Lyons, Woondong Jeong, Ramya Antony, Alice P. Chen, Len Neckers, James H. Doroshow, Shivaani Kummar

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib

Nagdeep Giri, Joanna C. Masters, Anna Plotka, Yali Liang, Tanya Boutros, Patricia Pardo, Joseph O’Connell, Carlo Bello

01.08.2015 | PHASE I STUDIES | Ausgabe 4/2015

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Karthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, Lim Soon Thye, Wee Joo Chng, Brigette Ma, Ming Huang Chen, Xiaofei Zhou, Hua Liu, Virginia Kelly, Won Seog Kim

01.08.2015 | PHASE II STUDIES | Ausgabe 4/2015

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study

Norisuke Nakayama, Atsushi Sato, Soichi Tanaka, Ken Shimada, Kazuo Konishi, Eisaku Sasaki, Kenji Hibi, Hiroko Ichikawa, Yoshinori Kikuchi, Toshikazu Sakuyama, Takashi Sekikawa, Kazuhiko Hayashi, Haruhiro Nishina, The Tokyo Cooperative Oncology Group, Tokyo, Japan

01.08.2015 | PHASE II STUDIES | Ausgabe 4/2015

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study

Katrina S. Pedersen, George P. Kim, Nathan R. Foster, Andrea Wang-Gillam, Charles Erlichman, Robert R. McWilliams

01.08.2015 | PHASE II STUDIES | Ausgabe 4/2015

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

B. J. Eigl, S. North, E. Winquist, D. Finch, L. Wood, S. S. Sridhar, J. Powers, J. Good, M. Sharma, J. A. Squire, J. Bazov, T. Jamaspishvili, M. E. Cox, P. A. Bradbury, E. A. Eisenhauer, K. N. Chi

01.08.2015 | PHASE II STUDIES | Ausgabe 4/2015

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

S. M. Reddy, S. Kopetz, J. Morris, N. Parikh, W. Qiao, M. J. Overman, D. Fogelman, I. Shureiqi, C. Jacobs, Z. Malik, C. A. Jimenez, R. A. Wolff, J. L. Abbruzzese, G. Gallick, C. Eng

01.08.2015 | PHASE II STUDIES | Ausgabe 4/2015

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

B. B. Y. Ma, B. C. Goh, W. T. Lim, E. P. Hui, E. H. Tan, G. de Lima Lopes, K. W. Lo, L. Li, H. Loong, N. R. Foster, C. Erlichman, A. D. King, M. K. M. Kam, S. F. Leung, K. C. Chan, A. T. C. Chan

01.08.2015 | REVIEW | Ausgabe 4/2015 Open Access

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy

Matthew Trendowski, Thomas P. Fondy

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.